ReviewCurrent rheumatology reports2014
Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice.
Review in Current rheumatology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Periostin and rheumatic diseases: early insights from a systematic review and meta-analysis.Clinical and experimental medicine · 2025Pooled it
- Trial
- Anti-citrullinated protein antibody response after primary EBV infection in kidney transplant patients.PloS one · 2018Trial
- COping with Rheumatic Stressors (CORS) questionnaire: validated German translation and cross-cultural adaptation for patients with axSpA.Journal of patient-reported outcomes · 2025Article
- Causal relationship between asthma and ankylosing spondylitis: A bidirectional two-sample univariable and multivariable Mendelian randomization study.Open medicine (Warsaw, Poland) · 2025Article
- Effects of serum inflammatory factors, health index and disease activity scores on ankylosing spondylitis patients with sleep disorder.World journal of psychiatry · 2024Article
- Immune-mediated lung diseases: A narrative review.Frontiers in medicine · 2023Review
- Prevalence of sleep disturbance and the association between poor disease control in people with ankylosing spondylitis within the Australian clinical setting (ASLEEP study): a real-world observational study using the OPAL dataset.Clinical rheumatology · 2022Observational
- Prevalence and factors related to sleep apnoea in ankylosing spondylitis.Clinical rheumatology · 2022Article
- Acute transverse myelitis revealing ankylosing spondylitis: A case report and literature review.Clinical case reports · 2021Article
- Membranous nephropathy and thymoma in a patient with ankylosing spondylitis: A case report.Medicine · 2020Article
- Ankylosing spondylitis and mortality following hospitalised pneumonia: a population-based cohort study.RMD open · 2020Article
- IgA and FcαRI: Versatile Players in Homeostasis, Infection, and Autoimmunity.ImmunoTargets and therapy · 2020Review
- HLA-B27 Negativity Is Associated With Renal Function Decline in Patients With Ankylosing Spondylitis and Secondary IgA Nephropathy.Frontiers in medicine · 2020Article
- Impact of ankylosing spondylitis on depression: a nationwide cohort study.Scientific reports · 2019Article
- Lumbar bone erosion with anterior dural ectasia in ankylosing spondylitis: a case report.The Journal of international medical research · 2019Article
- Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry.Rheumatology and therapy · 2018Article
- Healthcare Utilization and Direct Costs in Patients with Ankylosing Spondylitis Using a Large US Administrative Claims Database.Rheumatology and therapy · 2018Article
- Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set.Clinical rheumatology · 2018Article
- Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set.Journal of pharmaceutical health services research : an official journal of the Royal Pharmaceutical Society of Great Britain · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ankylosing spondylitis (AS) is associated with several comorbidities which contribute significantly to morbidity and mortality and add to the complexity of management. In addition to the well known extra-articular manifestations and increased cardiovascular risk, several pulmonary, renal, and neurological complications which have been associated with AS deserve equal attention. Whereas a clear link has been established for some manifestations, the evidence for other associations is less clear. Interstitial lung disease, apical fibrosis, secondary infection, and ventilatory restriction from reduced chest wall movement are well known pulmonary complications; more recently an association with sleep apnoea has been suggested. Renal amyloidosis and IgA nephropathy remain a treatment challenge which may respond to anti-TNF therapy. Atlanto axial subluxation and vertebral fractures can result in serious neurological complications and are notoriously difficult to diagnose unless a high level of suspicion is maintained. Despite several reports linking AS with demyelination a true link remains to be proved. This review discusses the prevalence, pathophysiology, and management of pulmonary, renal, and neurological complications, and implications for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.